AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Regulation FD Disclosure

AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

The following information and Exhibit99.1 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing.On March 8, 2019, AMAG Pharmaceuticals, Inc. (“the Company”) issued a press release announcing topline results from PROLONG (Progestin’s Role in Optimizing Neonatal Gestation), a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena®(hydroxyprogesterone caproate injection) in patients with a history of a prior spontaneous singleton preterm delivery. A copy of the Company’s press release is furnished herewith as Exhibit99.1.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

The Company hereby furnishes the following exhibits:

AMAG PHARMACEUTICALS INC. Exhibit
EX-99.1 2 ex9918k3819.htm EXHIBIT 99.1 Exhibit                     FOR IMMEDIATE RELEASEAMAG PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM THE PROLONG TRIAL EVALUATING MAKENA® (hydroxyprogesterone caproate injection)    WALTHAM,…
To view the full exhibit click here

About AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG)

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

An ad to help with our costs